Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19
Clinical Infectious Diseases · 16.08.2024 · 79 (2) · 354-363
DOI: 10.1093/cid/ciae159 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 01.05.2024. Verfasst von Carolyn T Bramante und 36 weiteren Autor:innen. Beteiligte Einrichtung: General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Metformin, Viral Load, SARS-CoV-2, COVID-19 Drug Treatment. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Metformin has antiviral activity against RNA viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression of protein translation via targeting the host mechanistic target of rapamycin pathway. In the COVID-OUT randomized trial for outpatient coronavirus disease 2019 (COVID-19), metformin reduced the odds of hospitalizations/death through 28 days by 58%, of emergency department visits/hospitalizations/death through 14 days by 42%, and of long COVID through 10 months by 42%.
Methods
COVID-OUT was a 2 × 3 randomized, placebo-controlled, double-blind trial that assessed metformin, fluvoxamine, and ivermectin; 999 participants self-collected anterior nasal swabs on day 1 (n = 945), day 5 (n = 871), and day 10 (n = 775). Viral load was quantified using reverse-transcription quantitative polymerase chain reaction.
Results
The mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (−0.56 log10 copies/mL; 95% confidence interval [CI], −1.05 to −.06; P = .027). Those who received metformin were less likely to have a detectable viral load than placebo at day 5 or day 10 (odds ratio [OR], 0.72; 95% CI, .55 to .94). Viral rebound, defined as a higher viral load at day 10 than day 5, was less frequent with metformin (3.28%) than placebo (5.95%; OR, 0.68; 95% CI, .36 to 1.29). The metformin effect was consistent across subgroups and increased over time. Neither ivermectin nor fluvoxamine showed effect over placebo.
Conclusions
In this randomized, placebo-controlled trial of outpatient treatment of SARS-CoV-2, metformin significantly reduced SARS-CoV-2 viral load, which may explain the clinical benefits in this trial. Metformin is pleiotropic with other actions that are relevant to COVID-19 pathophysiology. Clinical Trials Registration NCT04510194.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
- Genomics Center, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Surgery, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Carolyn T Bramante
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NIH HHS
- National Heart, Lung, and Blood Institute of the NIH
- NCATS NIH HHS
- Institute for Engineering in Medicine
- Minnesota's Rainwater Foundation Grant
- Fast Grants
Zitieren
APA
Bramante, C. T., Beckman, K. B., Mehta, T., Karger, A. B., Odde, D. J., Tignanelli, C. J., Buse, J. B., Johnson, D. M., Watson, R. H. B., Daniel, J. J., Liebovitz, D. M., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H. K., Siegel, L. K., Klatt, N. R., Anderson, B., Hartman, K. M., …, & COVID-OUT Study Team (2024). Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19. Clinical Infectious Diseases, 79(2), 354-363. https://doi.org/10.1093/cid/ciae159
Vancouver
Bramante CT, Beckman KB, Mehta T, Karger AB, Odde DJ, Tignanelli CJ, et al. Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19. Clinical Infectious Diseases. 2024;79(2):354-363. doi:10.1093/cid/ciae159
BibTeX
@article{Bramante2024,
author = {Bramante, Carolyn T and Beckman, Kenneth B and Mehta, Tanvi and Karger, Amy B and Odde, David J and Tignanelli, Christopher J and Buse, John B and Johnson, Darrell M and Watson, Ray H B and Daniel, Jerry J and Liebovitz, David M and Nicklas, Jacinda M and Cohen, Ken and Puskarich, Michael A and Belani, Hrishikesh K and Siegel, Lianne K and Klatt, Nichole R and Anderson, Blake and Hartman, Katrina M and Rao, Via and Hagen, Aubrey A and Patel, Barkha and Fenno, Sarah L and Avula, Nandini and Reddy, Neha V and Erickson, Spencer M and Fricton, Regina D and Lee, Samuel and Griffiths, Gwendolyn and Pullen, Matthew F and Thompson, Jennifer L and Sherwood, Nancy E and Murray, Thomas A and Rose, Michael R and Boulware, David R and Huling, Jared D and COVID-OUT Study Team, COVID-OUT Study Team},
title = {Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {79},
number = {2},
pages = {354--363},
doi = {10.1093/cid/ciae159}
}
EUVIMED